Labec Pharma to Distribute Interleukin Genetics' Test | GenomeWeb

NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has signed up Labec Pharma of Madrid to distribute its genetic test for heart attack risk in Spain and Portugal.

The Cardio Health test identifies multiple genetic variations that can lead to overproduction of certain chemicals that can cause inflammation, and can indicate "a statistically significant risk" for heart attack, the Waltham, Mass.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.